Is BeyondSpring Inc. (BYSI) a Buy, Sell, or Hold?
NASDAQ : BYSI
BeyondSpring Inc.
$1.29 USD
$0.01 (0.78%)
- Volume
- 12.48K
- Average Volume
- 21.82K
- Market Capitalization
- $53.04M
- P/E Ratio
- -6.79
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $2.44
- Year Low
- $1.16
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.09
Company Overview
NASDAQ
Qiu Min
Biotechnology
Healthcare
BYSI
44
US
USD
Liquidity Metrics
-0.01
1.09
1.09
0.33
0.00
Sales & Valuation
-$
0.00
-1.54
-2.78
-0.46
Profitability
-$0.2
-$7.99M
0.00%
0.00%
23.76%
-41.52%
P/E Metrics
-6.79
0.00
0.00
Analyst Price Target & Rating
2/5
9 Analysts
%
Poll Results
About BeyondSpring Inc. (NASDAQ:BYSI) Stock
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced through Phase III clinical trials for two distinct applications: the prevention of chemotherapy-induced neutropenia, and the treatment of advanced non-small cell lung cancer. The company is also exploring Plinabulin's efficacy in combination with various immuno-oncology drugs; specifically, alongside nivolumab (a PD-1 antibody) for NSCLC, and with nivolumab and ipilimumab (a CTLA-4 antibody) for small cell lung cancer (SCLC). Furthermore, it is being investigated in conjunction with PD-1 or PD-L1 antibodies and radiation to address a range of cancer ... s. Beyond its lead asset, BeyondSpring's pipeline includes three preclinical-stage small molecule immune agents and a proprietary drug development platform. The company, founded in 2010, maintains its headquarters in New York, New York.
2026-06-04 07:00:00
FLORHAM PARK, N.J., June 04, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage biopharmaceutical company developing first-in-class therapies for cancers with high unmet need, today announced a leadership transition designed to deliver focused, disciplined execution on BeyondSpring's most important near-term objective: completing DUBLIN-4, its confirmatory Phase 3 program for Plinabulin in non-squamous EGFR wild-type non-small cell lung cancer (NSCLC) with no driver mutation and post-immune checkpoint inhibitor (ICI). The leadership changes become effective July 1, 2026.
2026-06-02 07:00:00
Meaningful clinical benefit: Median PFS at 7. 0 months, median DoR is 9. 3 months with DCR of 79. 5% in metastatic NSCLC patients with acquired resistance to immune checkpoint inhibitors Durable survival benefit: 12-month OS rate of 78. 1% and 24-month OS rate of 58.
2026-06-02 07:00:00
FLORHAM PARK, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and other diseases, today announced updated efficacy and safety data from the investigator-initiated Phase 2 303 Study evaluating pembrolizumab plus Plinabulin and docetaxel in patients with metastatic non-small cell lung cancer (“NSCLC”) after progression on first-line immune checkpoint inhibitor (“ICI”) therapy, either alone or in combination with chemotherapy. The data were presented at the 2026 American Society of Clinical Oncology (“ASCO”) Annual Meeting by Dr. Mengzhao Wang and Dr. Yan Xu, principal investigators from Peking Union Hospital.
BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting
2026-05-18 07:00:00
FLORHAM PARK, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and other diseases, today announced an upcoming poster presentation of Study 303, an investigator-initiated study supported by Merck, known as MSD outside of the United States and Canada, and BeyondSpring, in patients with 2L/3L NSCLC who progressed on PD-1/PD-L1 inhibitors, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 through June 2 in Chicago, IL.
BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update
2026-05-13 07:00:00
AACR 2026 Data Positions Plinabulin as a Potential Backbone Agent to Combine with Antibody-Drug Conjugate (ADC)-Based Therapies to Improve Anti-Cancer Efficacy and Tolerability SEED Advances First Molecular Glue Degrader into Clinical Development with Biomarker-Driven Strategy FLORHAM PARK, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and other diseases, today announced its financial results for the quarter ended March 31, 2026, and provided a corporate update highlighting significant scientific and clinical advancements across its pipeline.
2026-04-22 07:00:00
New Preclinical Results at AACR 2026 Show Plinabulin Dramatically Improves Complete Response Rates and Survival When Combined with Leading ADC Drugs — With or Without Immunotherapy
Frequently Asked Questions
-
What is the current BeyondSpring Inc. (BYSI) stock price?
-
BeyondSpring Inc.(NASDAQ:BYSI) stock price is $1.29 in the last trading session. During the trading session, BYSI stock reached the peak price of $2.44 while $1.16 was the lowest point it dropped to. The percentage change in BYSI stock occurred in the recent session was 0.78% while the dollar amount for the price change in BYSI stock was $0.01.
-
BYSI's industry and sector of operation?
-
The NASDAQ listed BYSI is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BYSI?
-
June Lu | Chief Scientific Officer
Lan Huang | Co-Founder & Chair of the Board
Min Qiu | Chief Executive Officer
Joy Jia | Vice President of Finance
Li Na | Chief Financial Officer -
How many employees does BYSI have?
-
Number of BYSI employees currently stands at 44. BYSI operates from 100 Campus Drive, Florham Park, NY 10005, US.
-
Link for BYSI official website?
-
Official Website of BYSI is: https://www.beyondspringpharma.com
-
How do I contact BYSI?
-
BYSI could be contacted at phone #646 305 6387 and can also be accessed through its website. BYSI operates from 100 Campus Drive, Florham Park, NY 10005, US.
-
How many shares of BYSI are traded daily?
-
The average number of BYSI shares traded daily for last 3 months was 21.82K.
-
What is the market cap of BYSI currently?
-
The market value of BYSI currently stands at $53.04M with its latest stock price at $1.29